March 15, 2010 – Portola Pharmaceuticals and Merck announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. Results showed that a once-daily dose of oral betrixaban, given to patients with non-valvular atrial fibrillation or atrial flutter and at least one risk factor for stroke, reduced the incidence of major and clinically relevant non major (CRNM) bleeds compared to dose-adjusted warfarin.
The data were presented during a late-breaking clinical trials session at the American College of Cardiology (ACC) 59th Annual Scientific Session in Atlanta... [PDF] Portola Pharmaceuticals' Press Release - Merck's Press Release -
